The Tomosynthesis Mammography Imaging Screening Trial (TMIST), the largest-ever breast cancer screening trial, is designed to offer investigators data as to whether tomosynthesis (3-D mammography) is superior to 2D technology at finding and reducing the rate of potentially lethal cancers. The price tag is $100 million.
The study represents a randomized, Phase III trial evaluating digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment. The study is sponsored by ECOG-ACRIN Cancer Research Group with collaboration involving the National Cancer Institute and the Canadian Cancer Trials Group. The ongoing study targets 165,000 healthy women and runs all the way till 2030.
Who Can Enroll in TMIST?
Women ages 45 to 74 who are planning to get a routine screening mammogram are eligible for this trial. Women can also contact a participating site to ask about joining the study. Open sites are listed in the Locations & Contacts section of the trial record.
How to Enroll TMIST?
The trial is taking place in mammography clinics around the United States, with a few sites in Canada and Argentina. Eventually, there will be over 100 clinics taking part in the trial. When women call one of these participating clinics to schedule a routine mammograph, they may be asked to take part in TMIST.
Lear more about this study here.
Etta Pisano, ECOG-ACRIN Cancer Research Group